BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22151972)

  • 1. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias.
    Khalafallah A; Maiwald M; Hannan T; Abell S; Staker J; Supperamohan A
    Intern Med J; 2012 Feb; 42(2):131-6. PubMed ID: 22151972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Itraconazole 800 mg for the prophylaxis of fungal infections in patients with acute leukemia and severe neutropenia].
    Andrade M A; Puga L B; Guerra C C; Molina E J; Capurro C M
    Rev Med Chil; 2011 Sep; 139(9):1128-34. PubMed ID: 22215390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole.
    Barreto JN; Beach CL; Wolf RC; Merten JA; Tosh PK; Wilson JW; Hogan WJ; Litzow MR
    Am J Hematol; 2013 Apr; 88(4):283-8. PubMed ID: 23460251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
    Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
    Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
    Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
    J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
    Przepiorka D; Buadi FK; McClune B
    Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral voriconazole versus intravenous low dose amphotericin B for primary antifungal prophylaxis in pediatric acute leukemia induction: a prospective, randomized, clinical study.
    Mandhaniya S; Swaroop C; Thulkar S; Vishnubhatla S; Kabra SK; Xess I; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):e333-41. PubMed ID: 22042283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High risk febrile neutropenia in acute leukemia. The experience of a public hospital. National Program of Antineoplastic Drugs in Adult, Hospital del Salvador, 1991-2001].
    Puga B; Puga I; Cabrera ME; Undurraga MS; Guerra C; Urrejola G; Toro P
    Rev Med Chil; 2003 Sep; 131(9):1023-30. PubMed ID: 14635589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases.
    Park JS; Kim DH; Choi CW; Jeong SH; Choi JH; Kim K; Kim SJ; Jung CW; Yang DH; Jang JH
    Acta Haematol; 2010; 124(2):92-7. PubMed ID: 20664196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of micafungin for treating febrile neutropenia in hematological malignancies.
    Goto N; Hara T; Tsurumi H; Ogawa K; Kitagawa J; Kanemura N; Kasahara S; Yamada T; Shimizu M; Nakamura M; Matsuura K; Moriwaki H
    Am J Hematol; 2010 Nov; 85(11):872-6. PubMed ID: 20882524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for breakthrough invasive fungal infection during secondary prophylaxis.
    Cornely OA; Böhme A; Reichert D; Reuter S; Maschmeyer G; Maertens J; Buchheidt D; Paluszewska M; Arenz D; Bethe U; Effelsberg J; Lövenich H; Sieniawski M; Haas A; Einsele H; Eimermacher H; Martino R; Silling G; Hahn M; Wacker S; Ullmann AJ; Karthaus M;
    J Antimicrob Chemother; 2008 Apr; 61(4):939-46. PubMed ID: 18272515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Empirical antibiotic therapy in febrile neutropenic patients with acute leukemia].
    Yabe H; Nakamura F; Ishikawa T; Nagai K; Nakayama S
    Rinsho Ketsueki; 1989 May; 30(5):644-9. PubMed ID: 2795878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empiric antifungal therapy in patients with febrile neutropenia.
    Ferrara JJ; MacDougall C; Gallagher JC
    Pharmacotherapy; 2011 Apr; 31(4):369-85. PubMed ID: 21449626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of the serum Candida antigen titer for initiation of antifungal therapy after post-remission chemotherapy in patients with acute leukemia.
    Iwasaki H; Misaki H; Nakamura T; Ueda T
    Int J Hematol; 2000 Apr; 71(3):266-72. PubMed ID: 10846834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.
    Gupta A; Singh M; Singh H; Kumar L; Sharma A; Bakhshi S; Raina V; Thulkar S
    Med Oncol; 2010 Dec; 27(4):1037-45. PubMed ID: 19830601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis.
    Yeh TC; Liu HC; Hou JY; Chen KH; Huang TH; Chang CY; Liang DC
    Cancer; 2014 Apr; 120(8):1255-62. PubMed ID: 24415457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
    Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
    BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.